Ontada Illuminates the Power of its Real-World Evidence to Improve Health Outcomes for People with Cancer at ISPOR 2025
BOSTON--(BUSINESS WIRE)-- Ontada ®, a McKesson business and leader in community oncology real-world data, clinical education, and point of care technologies, today announced more than 14 abstracts at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2025 Annual Meeting taking place May 13-16, 2025 in Montreal, Canada. Ontada's presence at the conference includes a podium presentation and 13 research posters. Ontada researchers will also lead a workshop on successful models for growing patient engagement in health economic outcomes research and an issue panel on the readiness of social determinants of health data.
'Our extensive research portfolio underscores our commitment to driving meaningful advancements in patient care in oncology,' said Amy O'Sullivan, PhD, Senior Vice President and Chief Research Officer, Ontada. 'Our significant presence at ISPOR 2025 demonstrates the role we can play in powering important real world evidence generation evaluating the value, safety, and efficacy of cancer therapies in the real world.'
Highlights of Ontada's presence at ISPOR 2025 include:
Podium Presentation - Introduction of Distress Thermometer (DT) Screening in the US Community Oncology Setting: A Retrospective Study of Electronic Health Records (EHR) Integration: This study evaluated DT utilization following EHR implementation in 2023 across a large network of US community oncology clinics.
Poster - Evolving Real-world Trends in Biomarker Testing for Bladder Cancer: A Comprehensive Retrospective Analysis from the US Community Oncology Setting (2015-2024): This study examined real-world trends in biomarker testing for BC within a US community oncology network over the past decade.
Poster - Assessing the Correlation between Time to Metastatic Disease and Overall Survival in a Real-World Pan-Tumor Cohort: To understand the potential of TTMd as a proxy endpoint, this study assessed the relationship between TTMd and OS among patients with several solid tumor types in the community oncology setting.
Poster - Evidence for the Cumulative Impact of Social Determinants of Health (SDOH) on Cancer Mortality: A Scoping Review: This scoping review evaluated the breadth of evidence published on the relationship between SDOH and cancer mortality, aiming to distinguish key concepts, common methodologies, and knowledge gaps.
Poster - Development and Application of a Novel Framework for Clinician Stakeholder Engagement in Real-world Data (RWD) Studies: This study developed a conceptual framework for the integration of clinician stakeholder feedback into RWD investigations and report on three applied examples.
Poster - Accelerating EHR Insights: NLP-Driven Data Abstraction in Gallbladder Cancer: This study utilized natural language processing (NLP) to extract TNM staging and histology data from unstructured EHR documents to improve data completeness and accuracy.
Poster - Real-World Impact Of Recurrence On Overall Survival (OS) In Patients With Unresectable Locally Advanced (LA) Esophageal/Gastroesophageal Junction Cancer (EC/GEJC) Treated With Definitive Chemoradiotherapy (dCRT) In US Community Oncology Clinics: This study assessed the impact of recurrence on OS using real-world data.
Poster - Use of Sensitivity Analysis to Address Potential Missing Data and Selection Bias from Linked Genomics Datasets in a Real-World Study of Patients Receiving Immune-Checkpoint Inhibitors for Metastatic Melanoma: This study investigates the use of sensitivity analysis to address such bias from a linked genomics database in patients treated with immune-checkpoint inhibitors (ICI) for metastatic melanoma.
Poster - Utilizing NLP to Enhance EHR Data Abstraction Accuracy in Waldenström Macroglobulinemia: To improve data completeness and accuracy, natural language processing (NLP) was applied to extract diagnoses and dates from unstructured pathology reports for Waldenström macroglobulinemia (WM), a rare B-cell neoplasm.
Poster - Validation of Real-World Pathologic Complete Response in Early Stage Triple Negative Breast Cancer: This retrospective observational study examined the concordance between rwpCR and KEYNOTE-522 trial 'chemotherapy only' arm pCR estimates.
Poster - Real-World Treatment Patterns of First-Line (1L) Ibrutinib in Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL): Insights into Therapy Interruptions, Discontinuation and Next Treatment: Given the evolving treatment landscape and continued reliance on ibrutinib despite availability of newer targeted therapies, this real-world study aimed to characterize treatment patterns in CLL/SLL patients who began first-line (1L) ibrutinib-based regimens between 11/21/2019 and 7/31/2023 in The US Oncology Network.
Poster - : This study aims to summarize and implement new real-world data (RWD) quality frameworks and initiatives to improve the relevance, reliability, and external validity of oncology EHR-derived databases for research.
Poster - Real-World Breast Cancer gene 1 (BRCA1) and Breast Cancer gene 2 (BRCA2) Testing Trends by Race for Patients with Metastatic Prostate Cancer (mPC) from 2015 to 2024 in the Community Oncology Setting in the United States (US): This real-world analysis evaluated BCRA1/2 testing trends by race among patients with mPC within a large network of US community practices.
Poster - Validation of Real-World Recurrence-Free Survival (rwRFS) and Distant Metastasis-Free Survival(rwDMFS) Endpoints in Early-Stage Melanoma: This study applied trial emulation methods to examine the concordance between rREFS and rwDMFS estimates from the KEYNOTE-716 trial as a measure of real-world endpoint validity.
Issue Panel - Are Social Determinants of Health (SDoH) Data Ready for Primetime?: This session will debate the readiness of SDoH data to inform our efforts to address health disparities in the US.
Workshop - Integrating the Patient Voice: Successful Models of Continuous Engagement Science (CES) That Advance Data Science and Drug Development: This workshop will describe CES strategies to enhance trustworthiness in health economics and outcomes research (HEOR) studies among patients, the public, and other decision-maker communities.
For a comprehensive list of abstracts and presentations, visit Ontada's ISPOR 2025 Site.
Additionally, visit the Ontada Booth (#1221) at the Montreal Convention Centre from May 13-16 to explore the data presented at ISPOR 2025 and experience Ontada's solutions firsthand.
About Ontada ®
Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer. Part of McKesson Corporation, Ontada was founded on the core belief that precise insights – delivered exactly at the point of need – can save more patients' lives. We connect the full patient journey by combining technologies used by The US Oncology Network and other community oncology providers with real-world data and research relied on by all top 15 global life sciences companies. Our work helps accelerate innovation and powers the future of cancer care. For more information, visit ontada.com.
About McKesson Oncology and Specialty Solutions
It's an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care.
McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through its joint venture, Sarah Cannon Research Institute.
The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers.
Ontada ®, a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE), and provides clinical education and provider technology to inform and improve cancer care.
As a leading distributor of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them.
And through CoverMyMeds, Biologics by McKesson, and GPO services, our work continues to help patients access, afford, and adhere to their medicines.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo DAZALS met its secondary endpoint of improved overall survival at week 24 of the study in patients who received 300 mg of dazucorilant compared to patients who received placebo Exploratory analysis at the one-year mark shows continued significant improvement in overall survival between patients who received 300 mg of dazucorilant and those who received placebo only Corcept seeking guidance from United States and European regulators on optimum path forward REDWOOD CITY, Calif., June 05, 2025--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting. The presentation can be found here. DAZALS is a randomized, double-blind, placebo-controlled Phase 2 study in which 249 patients with ALS were randomized to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo, daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in a long-term extension study in which all patients received 300 mg of dazucorilant. The primary endpoint in DAZALS was the difference in ALSFRS-R between patients who received dazucorilant and those who received placebo. Overall survival was a secondary endpoint. Although DAZALS did not meet its primary endpoint, patient survival significantly improved. At week 24 of the study, no deaths had occurred in the 83 patients who received 300 mg of dazucorilant, while there were five deaths in the 82-patient placebo group (p-value of 0.02). An exploratory analysis conducted at the one-year mark shows the survival benefit has continued. Patients randomized to 300 mg of dazucorilant lived significantly longer than patients who received placebo and did not switch to 300 mg of dazucorilant in the extension study. The difference between groups was pronounced, with a hazard ratio of 0.16 (p-value: 0.0009). See Figure 1. A similar survival benefit was observed in patients who received 300 mg of dazucorilant for greater than 24 weeks, either in the treatment period or in the extension study, compared to patients who received either placebo or 150 mg of dazucorilant for 24 weeks and did not receive dazucorilant in the extension study (hazard ratio: 0.36; p-value 0.02). See Figure 2. The extension study is ongoing. Dazucorilant has demonstrated an acceptable safety profile, with 92 percent of adverse events being mild to moderate in severity. The frequency of severe and serious adverse events in patients who received dazucorilant was similar to those who received placebo. Mild to moderate, dose-related, transient abdominal pain was the most common adverse effect. "The improvement in overall survival, first noted in the DAZALS study at six months, continues to be seen at one-year. This finding deserves our full attention in service to patients with this tragic disease. Progress in the development of new ALS treatments is of critical importance," said Leonard H. van den Berg, M.D., Ph.D., Professor and Chair in the Department of Neurology, UMC Utrecht Brain Centre, Utrecht, The Netherlands, and Principal Investigator in the DAZALS study. "Medications that can extend life for patients with ALS are urgently needed. We are working with regulatory authorities to determine the optimal path for advancing dazucorilant," said Bill Guyer, PharmD, Corcept's Chief Development Officer. "We would like to thank the patients, their families and care partners, as well as the investigators, doctors and clinic staff involved in this study." About the DAZALS Study DAZALS is a randomized, double-blind, placebo-controlled Phases 2 trial in which 249 patients with ALS were randomized 1:1:1 to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in the long-term extension study in which all patients received 300 mg of dazucorilant. Baseline patient characteristics, including the ENCALS risk score, time from diagnosis, ALSFRS-R total score, and bulbar onset, were consistent across study arms. The DAZALS primary endpoint was the difference in change from baseline during the study's 24-week treatment period in ALSFRS-R score between patients who received dazucorilant and those who received placebo. Key secondary endpoints include overall survival and quality of life. DAZALS was conducted at sites in Europe, the United States and Canada. About Amyotrophic Lateral Sclerosis (ALS) ALS, also known as Lou Gehrig's disease or motor neuron disease, is a fatal degenerative neurologic disorder that affects more than 55,000 people in the United States and Europe. ALS causes muscles to weaken and, as the disease progresses, severely impairs patients' ability to speak, eat, move and breathe. There is increasing evidence that patients with ALS, particularly those with rapid disease progression, exhibit elevated or abnormal cortisol levels. A patient's life expectancy after diagnosis is two to five years. About Dazucorilant Dazucorilant is a selective cortisol modulator that binds to the glucocorticoid receptor but does not bind to the body's other hormone receptors. Corcept is studying it as a potential treatment for ALS and other neurologic disorders. Dazucorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. The U.S. Food and Drug Administration has granted dazucorilant Fast Track Designation and orphan drug status for the treatment of ALS in the United States. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations, which are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties are set forth in our SEC filings, which are available at our website and the SEC's website. In this press release, forward-looking statements include those concerning the development of dazucorilant as a treatment for patients with ALS, including the pace, conduct, timing and outcome of DAZALS and its associated long-term extension study, as well as oversight or requirements that may be imposed by the FDA or other regulatory authorities. We disclaim any intention or duty to update forward-looking statements made in this press release. View source version on Contacts Investor inquiries:ir@ Media inquiries:communications@
Yahoo
an hour ago
- Yahoo
Yumeiren International Group Shines at Malaysia's IBE
HANGZHOU, China, June 05, 2025--(BUSINESS WIRE)--The four-day 2025 Malaysia IBE (International Beauty Expo) concluded successfully in Kuala Lumpur. This year's event brought together over 400 international brands and attracted more than 16,000 professional buyers, forming a robust business network spanning 28 countries. As a leader in China's medical aesthetics going global, Yumeiren stood out at the expo with its integrated approach to life cosmetology, medical cosmetology, and greater health. The company invited Southeast Asian partners to join its service network—marking a strategic step in its global growth and advancing the international presence of China's medical cosmetology. From its founding in 1993 to its global debut in Kuala Lumpur, Yumeiren has spent 33 years shaping the sustained growth of a Chinese medical beauty brand. This is not merely business expansion—it is an industry evolution that has weathered economic cycles, embraced technological shifts, and bridged cultural divides. Under the leadership of President Yu Wenhong, Yumeiren built its foundation from the ground up, uniting lifestyle beauty and medical cosmetology into the Artistic Facial Shaping platform. With passion, vision, and professionalism, she guided the company into a new era of precision development—continuously enhancing service systems, integrating multidisciplinary health management, and expanding into the broader wellness space. Through strategic integration and innovation, Yumeiren launched its Forever Young Healthcare System, using science to slow aging and empowering individuals to take control of their health and longevity. Even before the expo began, numerous Malaysian organizations actively reached out to Yumeiren seeking collaboration. In response, President Yu Wenhong and her team arrived in Kuala Lumpur early to evaluate potential partners and begin training local doctors—ensuring seamless integration of Chinese aesthetic standards with Malaysian medical practices and establishing Yumeiren as part of the local ecosystem. During the expo, Yumeiren's booth drew large crowds. The team shared the company's growth story and brand strengths, deepening attendees' understanding and reinforcing confidence in the brand, while clearly communicating partnership expectations and value. With over 30 years of experience, Yumeiren has built a solid operational and brand framework that ensures reliability—earning lasting trust from clients and attracting an increasing number of committed partners. The success of this expo showcased Yumeiren's strengths and highlighted strong interest from global markets. Committed to delivering professional service, Yumeiren will continue bringing health, youth, and beauty to the world. View source version on Contacts Cathy Cai, ymrinternational@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Yumeiren International Group Shines at Malaysia's IBE
HANGZHOU, China--(BUSINESS WIRE)--The four-day 2025 Malaysia IBE (International Beauty Expo) concluded successfully in Kuala Lumpur. This year's event brought together over 400 international brands and attracted more than 16,000 professional buyers, forming a robust business network spanning 28 countries. As a leader in China's medical aesthetics going global, Yumeiren stood out at the expo with its integrated approach to life cosmetology, medical cosmetology, and greater health. The company invited Southeast Asian partners to join its service network—marking a strategic step in its global growth and advancing the international presence of China's medical cosmetology. From its founding in 1993 to its global debut in Kuala Lumpur, Yumeiren has spent 33 years shaping the sustained growth of a Chinese medical beauty brand. This is not merely business expansion—it is an industry evolution that has weathered economic cycles, embraced technological shifts, and bridged cultural divides. Under the leadership of President Yu Wenhong, Yumeiren built its foundation from the ground up, uniting lifestyle beauty and medical cosmetology into the Artistic Facial Shaping platform. With passion, vision, and professionalism, she guided the company into a new era of precision development—continuously enhancing service systems, integrating multidisciplinary health management, and expanding into the broader wellness space. Through strategic integration and innovation, Yumeiren launched its Forever Young Healthcare System, using science to slow aging and empowering individuals to take control of their health and longevity. Even before the expo began, numerous Malaysian organizations actively reached out to Yumeiren seeking collaboration. In response, President Yu Wenhong and her team arrived in Kuala Lumpur early to evaluate potential partners and begin training local doctors—ensuring seamless integration of Chinese aesthetic standards with Malaysian medical practices and establishing Yumeiren as part of the local ecosystem. During the expo, Yumeiren's booth drew large crowds. The team shared the company's growth story and brand strengths, deepening attendees' understanding and reinforcing confidence in the brand, while clearly communicating partnership expectations and value. With over 30 years of experience, Yumeiren has built a solid operational and brand framework that ensures reliability—earning lasting trust from clients and attracting an increasing number of committed partners. The success of this expo showcased Yumeiren's strengths and highlighted strong interest from global markets. Committed to delivering professional service, Yumeiren will continue bringing health, youth, and beauty to the world.
